Phase l and Phase ll Study of S-1 + oxaliplatin (SOX) + cetuximab as first Line therapy in metastatic colorectal cancer with EGFR-detectable and KRAS wild type

Trial Profile

Phase l and Phase ll Study of S-1 + oxaliplatin (SOX) + cetuximab as first Line therapy in metastatic colorectal cancer with EGFR-detectable and KRAS wild type

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Jan 2017

At a glance

  • Drugs Cetuximab (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Oxaliplatin (Primary)
  • Indications Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 21 Jan 2017 Results (n=92) of a sub analysis of JACCRO CC-05 and JACCRO CC-06 trials presented at the 2017 Gastrointestinal Cancers Symposium
    • 07 Jun 2016 Results (n=77) from this trial and other trial (UMIN000004197) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 18 Jan 2014 Interim results presented at the 2014 Gastrointestinal Cancers Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top